AKL Therapeutics > About AKL > Executive Team

David Miles: CEO

Commercial executive, previously Head of Inflammatory diseases, Europe at Pfizer. Linkedin

Alan Reynolds: CSO

Clinical Scientist, previously European Clinical Science Director for Inflammation at Wyeth/ Pfizer. Linkedin

Dr. Nicholas Larkins: CRO, Co-Founder

Clinician and scientist with research interests focusing on the manipulation of inflammatory pathways. Linkedin

Michael Martin: CFO

Investor and adviser to startup companies in bio-science and education. Former investment banker in London, New York, Paris. Linkedin

Wendy Richings Barrow: Regulatory

Healthcare Regulatory Consultant. 35 years at Lederle Laboratories/Pfizer in Regulatory Affairs Licensing & Acquisitions. Linkedin

David Sharples: Chair, Co-Founder

Serial entrepreneur, experienced in recruiting and supervising strong management teams, fund-raising, commercial deals and company trade sales. Linkedin